Epeius Biotechnologies’ Rexin-G Receives FDA Fast Track Designation For The Treatment Of Pancreatic Cancer
Submitted by Robert Lawrence on Thursday, 18 June 2009No Comment
Epeius Biotechnologies announced that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.
Leave a comment!